Key Takeaways
- Pfizer discontinued development of the oral GLP-1 agonist danuglipron for obesity due to a single case of acute liver injury in a pharmacokinetic trial.
Investor outlook for Pfizer’s oral GLP-1 agonist danuglipron was already dampened, but now the obesity drug has officially been discontinued,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?